Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
Pfizer (NYSE:PFE) has entered into a multi-year collaboration with Alloy Therapeutics to develop a new antibody discovery platform. Under the deal, Alloy will receive an upfront payment from Pfizer ...
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback